Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study

NCT04359290 is registered in ClinicalTrials.gov with Philipps University Marburg as lead sponsor.

NCT NCT04359290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04359290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study
Lead sponsor
Philipps University Marburg
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2020
Completion date
July 30, 2021
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ards, human, covid